TITLE

Construction of Opa-Positive and Opa-Negative Strains of Neisseria meningitidis to Evaluate a Novel Meningococcal Vaccine

AUTHOR(S)
Sadarangani, Manish; Claire Hoe, J.; Callaghan, Martin J.; Jones, Claire; Chan, Hannah; Makepeace, Katherine; Daniels-Treffandier, Hélène; Deadman, Mary E.; Bayliss, Christopher; Feavers, Ian; van der Ley, Peter; Pollard, Andrew J.
PUB. DATE
December 2012
SOURCE
PLoS ONE;Dec2012, Vol. 7 Issue 12, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Neisseria meningitidis is a major global pathogen causing invasive disease with a mortality of 5-10%. Most disease in developed countries is caused by serogroup B infection, against which there is no universal vaccine. Opacity-associated adhesin (Opa) proteins are major meningococcal outer membrane proteins, which have shown recent promise as a potential novel vaccine. Immunisation of mice with different Opa variants elicited high levels of meningococcal-specific bactericidal antibodies, demonstrating proof in principle for this approach. Opa proteins are critical in meningococcal pathogenesis, mediating bacterial adherence to host cells, and modulating human cellular immunity via interactions with T cells and neutrophils, although there are conflicting data regarding their effects on CD4+ T cells. We constructed Opapositive and Opa-negative meningococcal strains to allow further evaluation of Opa as a vaccine component. All four opa genes from N. meningitidis strain H44/76 were sequentially disrupted to construct all possible combinations of N. meningitidis strains deficient in one, two, three, or all four opa genes. The transformations demonstrated that homologous recombination of exogenous DNA into the meningococcal chromosome can occur with as little as 80 bp, and that minor sequence differences are permissible. Anti-Opa bactericidal antibody responses following immunisation of mice with recombinant Opa were specific to the Opa variant used in immunisation. No immunomodulatory effects were observed when Opa was contained within meningococcal outer membrane vesicles (OMVs), compared to Opa-negative OMVs. These observations support the incorporation of Opa in meningococcal vaccines.
ACCESSION #
84709504

 

Related Articles

  • Mucosal and systemic immune response against Neisseria meningitidis b induced by single time vaccination strategy. González, E.; Romeu, B.; Del Campo, J.; Acevedo, R.; Lastre, M.; Zayas, C.; Cuello, M.; Cabrera, O.; Balboa, J.; Nuñez, N.; Valdez, Y.; Fariñas, M.; Pérez, O. // Revista VacciMonitor (Vacunología y Temas Afines);May-Aug2009, Vol. 18 Issue 2, p73 

    Immunization is one of the most successful and cost-effective health interventions ever. Immunization have been helping to reduce child mortality, improving maternal health and combating infectious diseases. In spite of its, undisputed past success and promising future, however, immunization...

  • Mucosal immune response induced by proteoliposome and cochleate derived from serogroups B N. meningitidis. Del Campo, Judith; Lastre, Miriam; Zayas, Caridad; Acevedo, Reinaldo; González, Elizabeth; Romeu, Belkis; Cuello, Maribel; Cabrera, Osmir; Balboa, Julio; Sarandi, Ali M.; Pérez, Oliver // Revista VacciMonitor (Vacunología y Temas Afines);May-Aug2009, Vol. 18 Issue 2, p69 

    Mucosal vaccination offers attractive advantages to conventional systemic vaccination. Most pathogens enter or establish infection at mucosal surfaces. This represents an enormous challenge for vaccine development. Nevertheless, the availability of safe and effective adjuvants that function...

  • Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Jackson, Catherine; Lennon, Diana; Wong, Sharon; Yan, Jacqueline; Stewart, Joanna; Reid, Stewart; Oster, Philipp; Ypma, Ellen; Martin, Diana // Archives of Disease in Childhood;Aug2011, Vol. 96 Issue 8, p744 

    Background A New Zealand serogroup B meningococcal epidemic prompted trials of a strain-specific (B:4:P1.7-2,4) outer membrane vesicle vaccine (MeNZB). Methods Adults, school children, and infants provided serum after three MeNZB doses to evaluate antibody persistence via serum bactericidal...

  • Distinct Binding and Immunogenic Properties of the Gonococcal Homologue of Meningococcal Factor H Binding Protein. Jongerius, Ilse; Lavender, Hayley; Tan, Lionel; Ruivo, Nicola; Exley, Rachel M.; Caesar, Joseph J. E.; Lea, Susan M.; Johnson, Steven; Tang, Christoph M. // PLoS Pathogens;Aug2013, Vol. 9 Issue 8, p1 

    Neisseria meningitidis is a leading cause of sepsis and meningitis. The bacterium recruits factor H (fH), a negative regulator of the complement system, to its surface via fH binding protein (fHbp), providing a mechanism to avoid complement-mediated killing. fHbp is an important antigen that...

  • Evidence of Positive Darwinian Selection in Putative Meningococcal Vaccine Antigens. Fitzpatrick, David; Creevey, Christopher; McInerney, James // Journal of Molecular Evolution;Jul2005, Vol. 61 Issue 1, p90 

    Meningococcal meningitidis is a life-threatening disease. In Europe and the United States the majority of cases are caused by virulent meningococcal strains belonging to serogroup B. Presently there is no effective vaccine against serogroup B strains, as traditional vaccine antigens such as...

  • Development of New Vaccines against Meningococcal Disease. Bröker, Michael // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Dec2003, Vol. 53 Issue 12, p805 

    Meningococcal diseases continue to have a major public health impact in many countries. Five major groups of Neisseria meningitidis (A, B, C, V and W135) are responsible for most meningococal diseases. Plain polysaccharides vaccines for Neisseria meningitidis groups A, C, V and W-135 have been...

  • Modulation of Immune Response to Group C Meningococcal Conjugate Vaccine Given Intranasally to Mice Together with the LTK63 Mucosal Adjuvant and the Trimethyl Chitosan Delivery System. Baudner, Barbara C.; Morandi, Maurizio; Giuliani, Marzia M.; J. Coos Verhoef; Junginger, Hans E.; Costantino, Paolo; Rappuoli, Rino; Del Giudice, Giuseppe // Journal of Infectious Diseases;3/1/2004, Vol. 189 Issue 5, p828 

    Previous work had shown that the immunogenicity of conjugate vaccine against group C meningococci (CRM-MenC) is enhanced when it is delivered intranasally (inl) with mucosal adjuvants, such as mutants of the Escherichia coli enterotoxin (LT), and with delivery systems such as chitosan ...

  • Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age. Halperin, Scott A.; Baine, Yaela; Domachowske, Joseph B.; Aggarwal, Naresh; Simon, Michael; Langley, Joanne M.; McNeil, Shelly A.; Friedland, Leonard R.; Bianco, Veronique; Baccarini, Carmen I.; Miller, Jacqueline M. // Journal of the Pediatric Infectious Diseases Society;Mar2014, Vol. 3 Issue 1, p33 

    Background Universal immunization of adolescents against meningococcal disease with a quadrivalent meningococcal ACWY (MenACWY) conjugate vaccine is recommended in a number of countries. Methods In a randomized, controlled, observer-blinded, multicenter trial, 1016 participants, 10–25...

  • P64K AS A CARRIER PROTEIN OF NEISSERIA MENINGITIDIS PORIN A PEPTIDES. Sardiñas, G.; Gonzalez, S.; Garay, H. E.; Nazábal, C.; Reyes, O.; Silva, R. // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    Class 1 protein from the outer membrane of N. meningitidis is an attractive target for vaccine development. Previously, cyclic peptides corresponding to VR1 and VR2 regions of the meningococcal class1 protein have been designed and employed as candidate antigens with good results (1). To...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics